Fluoxetine and its active metabolite norfluoxetine disrupt estrogen synthesis in a co-culture model of the feto-placental unit

The effects of fluoxetine, one of the most prescribed selective serotonin-reuptake inhibitors (SSRIs) during pregnancy, and its active metabolite norfluoxetine were studied on placental aromatase (CYP19) and feto-placental steroidogenesis. Fluoxetine did not alter estrogen secretion in co-culture of fetal-like adrenocortical (H295R) and trophoblast-like (BeWo) cells used as a model of the feto-placental unit, although it induced CYP19 activity, apparently mediated by the serotonin (5-HT)2A receptor/PKC signaling pathway. Norfluoxetine decreased estrogen secretion in the feto-placental co-culture and competitively inhibited catalytic CYP19 activity in BeWo cells. Decreased serotonin transporter (SERT) activity in the co-culture was comparable to 17β-estradiol treatment of BeWo cells. This work shows that the complex interaction of fluoxetine and norfluoxetine with placental estrogen production, involves 5-HT-dependent and -independent mechanisms. Considering the crucial role of estrogens during pregnancy, our results raise concern about the impact of SSRI treatment on placental function and fetal health.

[1]  L. Mottron,et al.  Antidepressant Use During Pregnancy and the Risk of Autism Spectrum Disorder in Children. , 2016, JAMA pediatrics.

[2]  S. Bulun,et al.  Novel Promoter I.8 and Promoter Usage in the CYP19 (Aromatase) Gene , 2008, Reproductive Sciences.

[3]  S. Nakajin,et al.  Forskolin up-regulates aromatase (CYP19) activity and gene transcripts in the human adrenocortical carcinoma cell line H295R. , 2004, The Journal of endocrinology.

[4]  J. Petrik,et al.  Perinatal Administration of a Selective Serotonin Reuptake Inhibitor Induces Impairments in Reproductive Function and Follicular Dynamics in Female Rat Offspring , 2015, Reproductive Sciences.

[5]  M. Nilsen,et al.  The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension. , 2011, Cardiovascular research.

[6]  S Sasson.  Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor. , 1991, Pathologie-biologie.

[7]  S. Rasmussen,et al.  Patterns of Antidepressant Medication Use Among Pregnant Women in a United States Population , 2011, Journal of clinical pharmacology.

[8]  C. Guillemette,et al.  A chromatography/tandem mass spectrometry method for the simultaneous profiling of ten endogenous steroids, including progesterone, adrenal precursors, androgens and estrogens, using low serum volume , 2015, Steroids.

[9]  V. Ganapathy,et al.  Drugs of abuse and human placenta. , 2011, Life sciences.

[10]  C. Nemeroff,et al.  Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. , 1997, The Journal of pharmacology and experimental therapeutics.

[11]  T. Einarson,et al.  Newer antidepressants in pregnancy and rates of major malformations: a meta‐analysis of prospective comparative studies , 2005, Pharmacoepidemiology and drug safety.

[12]  M. van den Berg,et al.  2-Chloro-s-triazine herbicides induce aromatase (CYP19) activity in H295R human adrenocortical carcinoma cells: a novel mechanism for estrogenicity? , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  A. Coenen,et al.  Placental Transfer of SSRI and SNRI Antidepressants and Effects on the Neonate , 2009, Pharmacopsychiatry.

[14]  N. Harada,et al.  Unique regulation of expression of human aromatase in the placenta , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[15]  J. Guibourdenche,et al.  Oestradiol stimulates morphological and functional differentiation of human villous cytotrophoblast. , 1999, Placenta.

[16]  G. Braunstein.  CHAPTER 21 – Endocrine Changes in Pregnancy , 2011 .

[17]  H. Flynn,et al.  Depressive symptoms among pregnant women screened in obstetrics settings. , 2003, Journal of women's health.

[18]  T. Lau,et al.  Differential regulation of serotonin transporter cell surface expression , 2012 .

[19]  E. Simpson,et al.  Assay of aromatase activity. , 1991, Methods in enzymology.

[20]  Mark Walker,et al.  Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. , 2006, American journal of obstetrics and gynecology.

[21]  Lucie Blais,et al.  First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. , 2007, Birth defects research. Part B, Developmental and reproductive toxicology.

[22]  K. Maršál,et al.  Norepinephrine transporter (NET), serotonin transporter (SERT), vesicular monoamine transporter (VMAT2) and organic cation transporters (OCT1, 2 and EMT) in human placenta from pre-eclamptic and normotensive pregnancies. , 2004, Placenta.

[23]  A. Bérard,et al.  Use of antidepressants during pregnancy and the risk of spontaneous abortion , 2010, Canadian Medical Association Journal.

[24]  T. Veenstra,et al.  A Liquid Chromatography-Mass Spectrometry Method for the Simultaneous Measurement of 15 Urinary Estrogens and Estrogen Metabolites: Assay Reproducibility and Interindividual Variability , 2008, Cancer Epidemiology Biomarkers & Prevention.

[25]  M. Owens,et al.  Antidepressants in amniotic fluid: another route of fetal exposure. , 2006, The American journal of psychiatry.

[26]  H. Malm,et al.  Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). , 2010, Reproductive toxicology.

[27]  Cathy Vaillancourt,et al.  Quantitative PCR Pitfalls: The Case of the Human Placenta , 2012, Molecular Biotechnology.

[28]  R. N. Morais,et al.  Fluoxetine induces changes in the testicle and testosterone in adult male rats exposed via placenta and lactation , 2014, Systems biology in reproductive medicine.

[29]  A. Bérard.  Re: Association between Antidepressant Use during Pregnancy and Infants Born Small for Gestational Age , 2011 .

[30]  N. Harada,et al.  Post‐translational dual regulation of cytochrome P450 aromatase at the catalytic and protein levels by phosphorylation/dephosphorylation , 2014, The FEBS Journal.

[31]  L. Altshuler,et al.  Placental passage of antidepressant medications. , 2003, The American journal of psychiatry.

[32]  J. Morrison,et al.  Fluoxetine during pregnancy: impact on fetal development. , 2005, Reproduction, fertility, and development.

[33]  C. Vaillancourt,et al.  A Unique Co-culture Model for Fundamental and Applied Studies of Human Fetoplacental Steroidogenesis and Interference by Environmental Chemicals , 2014, Environmental health perspectives.

[34]  D. Bogen,et al.  Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. , 2005, JAMA.

[35]  Abraham Weizman,et al.  Opposite modulatory effects of ovarian hormones on rat brain dopamine and serotonin transporters , 1997, Brain Research.

[36]  C. Vaillancourt,et al.  Stability of reference proteins in human placenta: general protein stains are the benchmark. , 2012, Placenta.

[37]  C. Vaillancourt,et al.  Phosphorylation of JAK2 by serotonin 5-HT (2A) receptor activates both STAT3 and ERK1/2 pathways and increases growth of JEG-3 human placental choriocarcinoma cell. , 2011, Placenta.

[38]  U. Högberg,et al.  The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring , 2013, Front. Cell. Neurosci..

[39]  R. Platt,et al.  Use of antidepressant medications during pregnancy: a multisite study. , 2008, American journal of obstetrics and gynecology.

[40]  T. Klempan,et al.  Stimulation of serotonergic 5-HT2A receptor signaling increases placental aromatase (CYP19) activity and expression in BeWo and JEG-3 human choriocarcinoma cells. , 2011, Placenta.

[41]  C. Vaillancourt,et al.  Expression of placental serotonin transporter and 5-HT 2A receptor in normal and gestational diabetes mellitus pregnancies. , 2009, Reproductive biomedicine online.

[42]  E. Albrecht,et al.  The role of estrogen in the maintenance of primate pregnancy. , 2000, American journal of obstetrics and gynecology.

[43]  T. Einarson,et al.  Prevalence of Depression During Pregnancy: Systematic Review , 2004, Obstetrics and gynecology.

[44]  S. Wisniewski,et al.  Mother-infant antidepressant concentrations, maternal depression, and perinatal events. , 2011, The Journal of clinical psychiatry.

[45]  C. Watson,et al.  Intracellular signaling involved in estrogen regulation of serotonin reuptake , 2004, Molecular and Cellular Endocrinology.

[46]  C. Chambers,et al.  Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence , 2016, CNS Drugs.

[47]  S. Nikfar,et al.  Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. , 2006, Reproductive toxicology.

[48]  J. Hakkola,et al.  Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. , 1998, Critical reviews in toxicology.

[49]  A. Bérard,et al.  Duration of antidepressant use during pregnancy and risk of major congenital malformations , 2008, British Journal of Psychiatry.

[50]  T. Di Paolo,et al.  Oestradiol Modulation of Serotonin Reuptake Transporter and Serotonin Metabolism in the Brain of Monkeys , 2013, Journal of neuroendocrinology.

[51]  C. Mendelson,et al.  Identification of the regulatory regions of the human aromatase P450 (CYP19) gene involved in placenta-specific expression , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[52]  G. Koren,et al.  Perinatal Risks of Untreated Depression during Pregnancy , 2004, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[53]  R. Blakely,et al.  Protein Kinase C Activation Regulates Human Serotonin Transporters in HEK-293 Cells via Altered Cell Surface Expression , 1997, The Journal of Neuroscience.

[54]  M. D. de Vera,et al.  Antidepressant use during pregnancy and the risk of pregnancy-induced hypertension. , 2012, British journal of clinical pharmacology.

[55]  L. Jong‐van den Berg,et al.  Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study , 2015, European Journal of Epidemiology.